Arellano-Saldaña ME, Rodríguez-Silverio J, Morales-Osorio MG, Arenas-Sordo ML

Language: Spanish
References: 28
Page: 101-105
PDF size: 135.12 Kb.

ABSTRACT

Introduction: Prevalence of drooling in children with cerebral palsy is 58%. Only 33% is profuse. Drooling is extremely uncomfortable for the patient and his care providers as it impairs life quality all around the family environment. The objective was to evaluate the clinical effectiveness of type A botulinum toxin in the treatment of drooling. Patients and methods: This is a double blind, controlled clinical trial in pediatric patients aged 4-16 years, who have cerebral palsy and profuse or severe drooling. Two groups were compared: A (control, type-A 500 U botulinum toxin) and B (experimental, 0.9% sodium chloride). Scales of intensity and frequency of drooling and functional independence (WeeFIM) were applied at the beginning, four weeks later and at the end of the treatment (week eight). Results: During a period between January and August of 2012, 21 patients were included, 13 boys (62%) and 8 girls (38%), with age averaging 7.0 (4-16 years). Dose of Type-A botulinum toxin in each submaxillar gland was 15-25 U (mean dose of 21 U/gland). The statistical analysis was made by U Mann Whitney test, the scales of intensity and frequency of drooling and WeeFIM had a p = 0.005 at eight weeks, which is statistically significant. Conclusion: Type-A botulinum toxin is useful and safe for the treatment of profuse drooling in pediatric patients with cerebral palsy.

REFERENCES

1. Lim M, Mace A, Reza N, Sandhu G. Botulinum toxin in the management of sialorrhoea: a systematic review. Clin Otolaryngol. 2006; 31: 267-272.

2. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B et al. Executive Committee for the Definition of Cerebral palsy. Proposed definition and classification of cerebral palsy. Dev Med Child Neurol. 2005; 47 (8): 571-576.

3. Tahmassebi JF, Curzon ME. Prevalence of drooling in children with cerebral palsy attending special schools. Dev Med Child Neurol. 2003; 45 (9): 613-617.

4. Crysdale WS, McCann C, Roske L, Joseph M, Semenuk D, Chait P. Saliva control issues in the neurologically challenged. A 30 year experience in team management. Int J Pediatr Otorhinolaryngol. 2006; 70 (3): 519-527.

5. Brei TJ. Management of drooling. Semin in Pediatr Neurol. 2003; 10 (4): 265-270.

6. Erbguth FJ. Botulinum Toxin, a historical note. Lancet. 1998; 351: 1820.

7. Lal D, Hotaling AJ. Drooling. Curr Opin Otolaryngol Head Neck Surg. 2006; 14 (6): 381-386.

8. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity and inmunology. Muscle Nerve Suppl. 1997; 6: 156-168.

9. Brin MF. Basic and clinical aspects of BOTOX. Toxicon. 2009; 54 (5): 676-682.

10. Jongerius PH, Van Den Hoogen FJ, Van Limbeek J, Gabreëls FJ, van Hulst K, Rotteveel JJ. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics. 2004; 114 (3): 620-627.

11. Crysdale WS, McCann C, Roske L, Joseph M, Semenuk D, Chait P. Saliva control issues in the neurologically challenged: a 30 year experience in team management. Int J Pediatr Otorhinolaryngol. 2006; 70: 520-527.

12. Tan EK. Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations. Eur J Neurol. 2006; 13 (Suppl1): 60-64.

13. Reid SM, Johnstone MB, Westbury C, Rawicki B, Reddihough DS. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol. 2008; 50: 123-128.

14. Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia. 1988; 3 (2): 73-78.

15. WeeFIM System. Clinical Guide, Version 5.01. University at Buffalo, Buffalo NY; 2000.

16. Suskind DL, Tilton A. Clinical study of botulinum –a toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope. 2002; 112 (1): 73-81.

17. Carod Artal FJ. Tratamiento de la sialorrea en enfermedades neurológicas mediante inyecciones transcutáneas de toxina botulínica tipo A en las glándulas parótidas. Neurología. 2003; 18 (5): 280-284.

18. López VLJ, Morales AF. Nuevas aplicaciones de la toxina botulínica. Neurología. 1998; 13 (8): 388-394.

19. Lorenc ZP, Kenkel JM, Fagien S, Hirmand H, Nestor MS, Sclafani AP et al. A review of onabotulinumtoxina (Botox). Aesthet Surg J. 2013; 33 (1 Suppl): 9S-12S.

20. Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC. Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol. 2011; 26 (7): 838-843.

21. Scheffer AR, Erasmus C, van Hulst K, van Limbeek J, Jongerius PH, van den Hoogen FJ. Efficacy and duration of botulinum toxin treatment for drooling in 131 children. Arch Otolaryngol Head Neck Surg. 2010; 136 (9): 873-877.

22. Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double–blind placebo controlled trial. Clin Neurol Neurosurg. 2009; 111 (1): 79-82.

23. Banerjee KJ, Glasson C, O’Flaherty SJ. Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy. Dev Med Child Neurol. 2006; 48 (11): 883-887.

24. Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012; 11: CD008624.

25. Fuster-Torres MA, Berini-Aytés L, Gay-Escoda C. Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal. 2007; 12 (7): E511-517.

26. Savarese R, Diamond M, Elovic E, Millis SR. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil. 2004; 83 (4): 304-311.

27. Baird MW, Vargus-Adams J. Outcome measures used in studies of botulinum toxin in childhood cerebral palsy: a systematic review. J Child Neurol. 2010; 25 (6): 721-727.

28. Yalcinkaya EY, Caglar NS, Tugcu B, Tonbaklar A. Rehabilitation outcomes of children with cerebral palsy. J Phys Ther Sci. 2014; 26 (2): 285-289.